130 related articles for article (PubMed ID: 37975616)
1. CDK6: an attractive therapeutic target for T-ALL/LBL.
Li W; Hu JK; Hu MG
Expert Opin Ther Targets; 2023; 27(11):1087-1096. PubMed ID: 37975616
[TBL] [Abstract][Full Text] [Related]
2. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Wang H; Nicolay BN; Chick JM; Gao X; Geng Y; Ren H; Gao H; Yang G; Williams JA; Suski JM; Keibler MA; Sicinska E; Gerdemann U; Haining WN; Roberts TM; Polyak K; Gygi SP; Dyson NJ; Sicinski P
Nature; 2017 Jun; 546(7658):426-430. PubMed ID: 28607489
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.
Chilosi M; Doglioni C; Yan Z; Lestani M; Menestrina F; Sorio C; Benedetti A; Vinante F; Pizzolo G; Inghirami G
Am J Pathol; 1998 Jan; 152(1):209-17. PubMed ID: 9422538
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
5. CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia.
Jena N; Sheng J; Hu JK; Li W; Zhou W; Lee G; Tsichlis N; Pathak A; Brown N; Deshpande A; Luo C; Hu GF; Hinds PW; Van Etten RA; Hu MG
Leukemia; 2016 May; 30(5):1033-43. PubMed ID: 26707936
[TBL] [Abstract][Full Text] [Related]
6. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
7. [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
Pan Y; Li GD; Liu WP; Zhang WY; Tang Y; Li FY
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):810-5. PubMed ID: 20193455
[TBL] [Abstract][Full Text] [Related]
8. KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo.
Pekkonen P; Järviluoma A; Zinovkina N; Cvrljevic A; Prakash S; Westermarck J; Evan GI; Cesarman E; Verschuren EW; Ojala PM
Cell Cycle; 2014; 13(23):3670-84. PubMed ID: 25483078
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
Huang YH; Wan CL; Dai HP; Xue SL
Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
[TBL] [Abstract][Full Text] [Related]
10. Precursor B- or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma.
Lee WJ; Moon HR; Won CH; Chang SE; Choi JH; Moon KC; Lee MW
J Am Acad Dermatol; 2014 Feb; 70(2):318-25. PubMed ID: 24314877
[TBL] [Abstract][Full Text] [Related]
11. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
[TBL] [Abstract][Full Text] [Related]
12. Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.
Porazzi P; De Dominici M; Salvino J; Calabretta B
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573335
[TBL] [Abstract][Full Text] [Related]
13. Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis.
Gary JM; Simmons JK; Xu J; Zhang S; Peat TJ; Watson N; Gamache BJ; Zhang K; Kovalchuk AL; Michalowski AM; Chen JQ; Thaiwong T; Kiupel M; Gaikwad S; Etienne M; Simpson RM; Dubois W; Testa JR; Mock BA
Mol Cancer Ther; 2020 Oct; 19(10):2221-2232. PubMed ID: 32747423
[TBL] [Abstract][Full Text] [Related]
14. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
De Dominici M; Porazzi P; Xiao Y; Chao A; Tang HY; Kumar G; Fortina P; Spinelli O; Rambaldi A; Peterson LF; Petruk S; Barletta C; Mazo A; Cingolani G; Salvino JM; Calabretta B
Blood; 2020 Apr; 135(18):1560-1573. PubMed ID: 32040545
[TBL] [Abstract][Full Text] [Related]
16. Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia.
Gao X; Qin S; Wu Y; Chu C; Jiang B; Johnson RH; Kuang D; Zhang J; Wang X; Mehta A; Tew KD; Leone GW; Yu XZ; Wang H
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34255748
[TBL] [Abstract][Full Text] [Related]
17. T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
Hoelzer D; Gökbuget N
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S214-21. PubMed ID: 19778844
[TBL] [Abstract][Full Text] [Related]
18. Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph
De Dominici M; Porazzi P; Soliera AR; Mariani SA; Addya S; Fortina P; Peterson LF; Spinelli O; Rambaldi A; Martinelli G; Ferrari A; Iacobucci I; Calabretta B
Cancer Res; 2018 Feb; 78(4):1097-1109. PubMed ID: 29233926
[TBL] [Abstract][Full Text] [Related]
19. Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia.
Bontoux C; Simonin M; Garnier N; Lhermitte L; Touzart A; Andrieu G; Bruneau J; Lengliné E; Plesa A; Boissel N; Baruchel A; Bertrand Y; Molina TJ; Macintyre E; Asnafi V
Mod Pathol; 2022 Sep; 35(9):1227-1235. PubMed ID: 35562412
[TBL] [Abstract][Full Text] [Related]
20. Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia.
Bride KL; Hu H; Tikhonova A; Fuller TJ; Vincent TL; Shraim R; Li MM; Carroll WL; Raetz EA; Aifantis I; Teachey DT
Haematologica; 2022 Aug; 107(8):1746-1757. PubMed ID: 34937317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
